NUDT6 Inhibitors

Chemical inhibitors of NUDT6 can exert their functional inhibitory effects through interference with various cellular signaling pathways in which NUDT6 is involved. Suramin, a growth factor receptor inhibitor, hampers the function of FGF receptors, which NUDT6 is associated with through its anti-sense RNA regulation of FGF-2. This disruption can lead to a decrease in FGF-2 signaling, thereby inhibiting the physiological functions of NUDT6. Similarly, PD173074, a selective FGFR inhibitor, directly targets FGFR, leading to a downstream reduction in FGF-2 mediated processes, which in turn inhibits NUDT6 activity. LY294002 and Wortmannin, both PI3K inhibitors, can halt the PI3K/AKT pathway, which is downstream of FGF-2 signaling. Since NUDT6 is potentially implicated in this pathway, such inhibition can suppress its function. Additionally, U0126 and PD0325901, as inhibitors of MEK1/2, disrupt the MAPK/ERK pathway, resulting in the inhibition of NUDT6 due to its putative involvement in this pathway. SP600125 and SB203580, which target JNK and p38 MAPK respectively, can also inhibit the MAPK pathway and therefore the function of NUDT6. Further, Dorsomorphin, by inhibiting BMP signaling, can indirectly hinder NUDT6 activity, presuming that NUDT6 acts within these pathways. Rapamycin, an mTOR inhibitor, can suppress cell growth and proliferation signals that are downstream of FGF-2, which NUDT6 may regulate, leading to its functional inhibition. The ROCK inhibitor Y-27632 can alter the actin cytoskeleton organization, a process that can be influenced by FGF-2 signaling. This alteration can restrict the cellular functions where NUDT6 is involved. ZM 447439, an Aurora kinase inhibitor, affects cell cycle and mitosis, which are cellular events where NUDT6 could play a role through the FGF-2 signaling pathway, leading to the inhibition of NUDT6..